Addition of oral iron bisglycinate to intravenous iron sucro
According to a recent study, intravenous iron sucrose for the treatment of postpartum anemia is sufficient. The study was published in the American Journal of Obstetrics & Gynecology.

The objective was to compare the efficacy of intravenous iron sucrose alone versus intravenous iron sucrose in combination with oral iron bisglycinate supplementation in treating moderate to severe postpartum anemia.

A randomized controlled trial was conducted. Women with postpartum hemoglobin <9.5g/dL were treated with 500 mg intravenous iron sucrose after an anemia workup, which ruled out other causes for anemia. In addition to receiving intravenous iron, women were randomly allocated to receive either oral 60 mg of iron bisglycinate for 45 days, or no further iron supplementation. The primary outcome was hemoglobin level at 6 weeks postpartum. Secondary outcomes were iron storage parameters and quality of life.

- Although statically significant, postpartum hemoglobin levels were only 0.4 g/dL higher in the intravenous and oral iron compared to intravenous iron-only cohort, with a respective increase from baseline of 4.2 g/dL versus 3.7 g/dL.

- There was no difference in the rate of women with hemoglobin<12.0 or 11.0 g/dL.

- Iron storage and health quality were also not different between the cohorts.

- Oral iron treatment was associated with a 29% rate of adverse effects. Compliance and satisfaction from treatment protocol were high in both cohorts.

Conclusively, intravenous 500 mg iron sucrose treatment alone is sufficient to treat postpartum anemia without the necessity of adding oral iron treatment.